ALKS stock · REGN stock

ALKS vs REGN

Alkermes Plc (ALKS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.

Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.

Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.

Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.

Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.

ALKS currently screens at market cap $4.78B and trailing P/E 13.8. REGN currently screens at market cap $59.10B and trailing P/E 13.9.

Not investment advice. Open the ALKS and REGN stock pages for the full models.

Not investment advice.

Popular Stock Comparisons